• Company
• Strong performance of overseas subsidiaries of companies
• by Kim, Jin-Gu Aug 22, 2022 05:52am

• Company
• Avastin biosimilar Vegzelma has obtained a European license
• by Kim, Jin-Gu Aug 22, 2022 05:52am

• Policy
• The PVA exception to COVID-19 cold drug is actively applied
• by Lee, Tak-Sun Aug 22, 2022 05:52am

• Company
• Ibrance safety is OK even in male breast cancer patients
• by Eo, Yun-Ho Aug 19, 2022 05:53am

• Policy
• Manufacturing for development allowed during suspensions
• by Lee, Hye-Kyung Aug 19, 2022 05:53am

• Company
• US FDA approves Samsung Bioepis' high conc Humira biosimilar
• by Kim, Jin-Gu Aug 19, 2022 05:53am

• Policy
• We need to increase the rate of PO tx for COVID-19 crisis
• by Lee, Jeong-Hwan Aug 19, 2022 05:53am

• Company
• Indication of Norvatis Beovu's DME was expanded
• by Aug 19, 2022 05:52am

• Company
• Why is the exp. date of the Sanofi flu vaccine short?
• by Aug 18, 2022 01:06pm

• Company
• Yuhan invests ₩23.1B in Yuhan USA over 4 years
• by Chon, Seung-Hyun Aug 18, 2022 05:48am